Arete Wealth Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Arete Wealth Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,246	Closed	-$367K	–	386
2021 Q1	$367K	Sell	12,246 -1,690	-12%	-$55K	0.05%	288
2020 Q4	$442K	Buy	13,936 +200	+1%	+$6K	0.06%	250
2020 Q3	$367K	Hold	13,736	–	–	0.06%	261
2020 Q2	$372K	Hold	13,736	–	–	0.06%	261
2020 Q1	$268K	Hold	13,736	–	–	0.05%	255
2019 Q4	$322K	Buy	+13,736	New	+$291K	0.06%	284

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LWPC

Legacy Wealth Partners (California) Calabasas, California $180M AUM 48.85% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Arete Wealth Advisors's CNCR Position: Q2 2021 in Review

Arete Wealth Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2021, closing a stake of 12,246 shares — an estimated $367K sold.

Arete Wealth Advisors first reported a position in CNCR in Q4 2019 and held it in 6 quarters. The position peaked at $442K in Q4 2020. 21 funds tracked by Wall St. Rank hold CNCR as of Q2 2021.

Arete Wealth Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2021 after selling out during the quarter.
Arete Wealth Advisors sold 12,246 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2021, an estimated $367K.
Arete Wealth Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2019 and held it in 6 quarters.
Arete Wealth Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $442K in Q4 2020.
21 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2021.

Based on Arete Wealth Advisors's 13F filing for Q2 2021, filed 9 Aug 2021.